Free Trial

This company has been marked as potentially delisted and may not be actively trading.

AzurRx BioPharma (AZRX) Competitors

AzurRx BioPharma logo

AZRX vs. IBIO, AEON, OBSV, AEZS, NRBO, ORGS, CPHI, MTNB, SPRB, and NBY

Should you be buying AzurRx BioPharma stock or one of its competitors? The main competitors of AzurRx BioPharma include iBio (IBIO), AEON Biopharma (AEON), ObsEva (OBSV), Aeterna Zentaris (AEZS), NeuroBo Pharmaceuticals (NRBO), Orgenesis (ORGS), China Pharma (CPHI), Matinas Biopharma (MTNB), Spruce Biosciences (SPRB), and NovaBay Pharmaceuticals (NBY). These companies are all part of the "medical" sector.

AzurRx BioPharma vs. Its Competitors

iBio (NYSE:IBIO) and AzurRx BioPharma (NASDAQ:AZRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations, profitability and media sentiment.

iBio has higher revenue and earnings than AzurRx BioPharma.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
iBio$375K32.58-$24.91MN/AN/A
AzurRx BioPharmaN/AN/A-$32.67M-$11.50-0.04

7.9% of iBio shares are owned by institutional investors. Comparatively, 6.3% of AzurRx BioPharma shares are owned by institutional investors. 0.6% of iBio shares are owned by insiders. Comparatively, 7.3% of AzurRx BioPharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, iBio's average media sentiment score of 0.00 equaled AzurRx BioPharma'saverage media sentiment score.

Company Overall Sentiment
iBio Neutral
AzurRx BioPharma Neutral

iBio has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500. Comparatively, AzurRx BioPharma has a beta of 1.51, suggesting that its share price is 51% more volatile than the S&P 500.

iBio's return on equity of -73.15% beat AzurRx BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
iBioN/A -73.15% -45.51%
AzurRx BioPharma N/A -482.96%-258.47%

iBio presently has a consensus target price of $5.00, suggesting a potential upside of 576.04%. Given iBio's stronger consensus rating and higher possible upside, research analysts plainly believe iBio is more favorable than AzurRx BioPharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
iBio
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
AzurRx BioPharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

iBio beats AzurRx BioPharma on 8 of the 10 factors compared between the two stocks.

Get AzurRx BioPharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for AZRX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AZRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AZRX vs. The Competition

MetricAzurRx BioPharmaPharmaceutical Preparations IndustryMedical SectorNASDAQ Exchange
Market Cap$4.59M$815.42M$5.72B$9.48B
Dividend YieldN/A4.84%4.59%3.98%
P/E Ratio-0.051.3827.9219.95
Price / SalesN/A24.93441.30102.64
Price / CashN/A19.5636.5558.97
Price / Book-0.656.818.635.90
Net Income-$32.67M-$4.28M$3.24B$258.42M

AzurRx BioPharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AZRX
AzurRx BioPharma
N/A$0.49
-0.6%
N/A-52.0%$4.59MN/A-0.0512Gap Up
IBIO
iBio
1.4709 of 5 stars
$0.72
-5.2%
$4.30
+493.2%
-66.9%$11.98M$375K0.00100
AEON
AEON Biopharma
2.6961 of 5 stars
$0.80
-4.3%
$360.00
+44,956.3%
-99.5%$9.03MN/A4.445Gap Down
OBSV
ObsEva
N/AN/AN/AN/A$7.94MN/A-0.1150
AEZS
Aeterna Zentaris
N/A$3.62
+2.5%
N/A-22.8%$6.49M$2.37M-0.2420Gap Down
NRBO
NeuroBo Pharmaceuticals
N/A$0.71
-1.1%
N/A-83.9%$6.12MN/A0.0010High Trading Volume
ORGS
Orgenesis
1.8339 of 5 stars
$1.19
+0.8%
N/AN/A$5.71M$662K0.00150Gap Up
CPHI
China Pharma
0.6005 of 5 stars
$1.70
-10.1%
N/A-93.2%$5.55M$4.30M0.00250Gap Down
High Trading Volume
MTNB
Matinas Biopharma
N/A$0.99
-1.0%
N/AN/A$5.04MN/A-0.2030Gap Down
SPRB
Spruce Biosciences
1.9907 of 5 stars
$0.10
-6.3%
$1.75
+1,711.6%
-76.6%$4.08M$4.91M-0.1020News Coverage
Stock Split
Gap Down
NBY
NovaBay Pharmaceuticals
1.6687 of 5 stars
$0.67
-2.9%
$0.85
+26.9%
-69.2%$3.90M$9.78M-0.0130

Related Companies and Tools


This page (NASDAQ:AZRX) was last updated on 7/24/2025 by MarketBeat.com Staff
From Our Partners